HAHA--nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology.
Immunogenicity induced by passively applied proteins is a serious issue because it is directly related to the patient's safety. The out-come of an immune reaction to a therapeutic protein can range from transient appearance of antibodies without any clinical significance to severe life threatening conditions. Within this article, enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR) methodology to measure immunogenicity are compared and the pros and cons are discussed.
Nechansky
Andreas
A
Vela pharmazeutische Entwicklung und Laboranalytik GmbH, Brunner Strasse 69, Vienna, Austria. a.nechansky@vela-labs.at
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D020349:Surface Plasmon Resonance / Q000379:methods*
D000911:Antibodies, Monoclonal